| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Advancing integration: progress reported for skin NTDs
|
Jesudason, Timothy
|
|
|
25 |
5 |
p. e263
|
artikel
|
| 2 |
Albendazole and ivermectin co-formulation for soil-transmitted helminthiases
|
Buonfrate, Dora
|
|
|
25 |
5 |
p. 478-479
|
artikel
|
| 3 |
Albendazole–ivermectin co-formulation for the treatment of Trichuris trichiura and other soil-transmitted helminths: a randomised phase 2/3 trial
|
Krolewiecki, Alejandro
|
|
|
25 |
5 |
p. 548-559
|
artikel
|
| 4 |
A perspective on the 2021 GBD study of diarrhoeal diseases
|
Muhsen, Khitam
|
|
|
25 |
5 |
p. 474-476
|
artikel
|
| 5 |
Approaches to increase access to community-based infectious disease control for ethnically, racially, and religiously marginalised populations: a scoping review
|
Epling, Seth W M
|
|
|
25 |
5 |
p. e269-e279
|
artikel
|
| 6 |
Breadth of immune response, immunogenicity, reactogenicity, and safety for a pentavalent meningococcal ABCWY vaccine in healthy adolescents and young adults: results from a phase 3, randomised, controlled observer-blinded trial
|
Nolan, Terry
|
|
|
25 |
5 |
p. 560-573
|
artikel
|
| 7 |
Chronic intestinal spirochaetosis and Giardia lamblia infection mimicking eosinophilic enterocolitis
|
De Francesco, Maria Antonia
|
|
|
25 |
5 |
p. e307-e313
|
artikel
|
| 8 |
Cornelia Lass-Flörl— Austria's global expert in mycology
|
Kirby, Tony
|
|
|
25 |
5 |
p. 489
|
artikel
|
| 9 |
Correction to Lancet Infect Dis 2017; 17: 804–05
|
|
|
|
25 |
5 |
p. e261
|
artikel
|
| 10 |
Correction to Lancet Infect Dis 2025; 25: 280–93
|
|
|
|
25 |
5 |
p. e261
|
artikel
|
| 11 |
Disseminated tuberculosis with gastrointestinal involvement caused by Mycobacterium bovis in a patient after liver transplantation
|
Mester, Patricia
|
|
|
25 |
5 |
p. e314-e315
|
artikel
|
| 12 |
DR Congo's conflict and cholera: a call for ring vaccination
|
Al-Rabeeah, Abdullah A
|
|
|
25 |
5 |
p. e260
|
artikel
|
| 13 |
Drug misuse in prisons in Eastern Europe and Central Asia
|
Holt, Ed
|
|
|
25 |
5 |
p. e265
|
artikel
|
| 14 |
Effectiveness of ceftazidime–avibactam versus ceftolozane–tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study
|
Shields, Ryan K
|
|
|
25 |
5 |
p. 574-584
|
artikel
|
| 15 |
Elisabeth Presterl—always looking forward
|
Kazi, Farooq
|
|
|
25 |
5 |
p. 490
|
artikel
|
| 16 |
Gavi under threat from US funding cuts
|
Burki, Talha
|
|
|
25 |
5 |
p. e266-e267
|
artikel
|
| 17 |
Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM
|
Cornely, Oliver A
|
|
|
25 |
5 |
p. e280-e293
|
artikel
|
| 18 |
Global, regional, and national age-sex-specific burden of diarrhoeal diseases, their risk factors, and aetiologies, 1990–2021, for 204 countries and territories: a systematic analysis for the Global Burden of Disease Study 2021
|
|
|
|
25 |
5 |
p. 519-536
|
artikel
|
| 19 |
Hecolin vaccination strategies for hepatitis E outbreak control in resource-constrained settings
|
Zhuang, Chunlan
|
|
|
25 |
5 |
p. 476-478
|
artikel
|
| 20 |
Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study
|
Alves, Katia
|
|
|
25 |
5 |
p. 585-594
|
artikel
|
| 21 |
Infectious disease surveillance update
|
McQuillan, Cahal
|
|
|
25 |
5 |
p. e267
|
artikel
|
| 22 |
Interim analysis of SARS-CoV-2 vaccine NVX-CoV2601 as a heterologous booster dose
|
Yadav, Pragya D
|
|
|
25 |
5 |
p. 484-485
|
artikel
|
| 23 |
King Kennard Holmes
|
Bagcchi, Sanjeet
|
|
|
25 |
5 |
p. 488
|
artikel
|
| 24 |
Lessons from the COVID-19 pandemic
|
Haslam, Elizabeth
|
|
|
25 |
5 |
p. 494
|
artikel
|
| 25 |
Measles in Texas: waning vaccination and a stark warning for public health
|
Kuppalli, Krutika
|
|
|
25 |
5 |
p. 485-487
|
artikel
|
| 26 |
Michael Ramharter—tackling tropical infectious diseases
|
Samarasekera, Udani
|
|
|
25 |
5 |
p. 491
|
artikel
|
| 27 |
Missed opportunities for equity: a crucial perspective on the Lancet's Zika virus research Series
|
Almeida, Bethânia de Araújo
|
|
|
25 |
5 |
p. e258
|
artikel
|
| 28 |
MMV533, a promising new antimalarial on the horizon
|
Dondorp, Arjen M
|
|
|
25 |
5 |
p. 473-474
|
artikel
|
| 29 |
Operationalising antimicrobial resistance surveillance data in conflict areas
|
Potochilova, Viktoria V
|
|
|
25 |
5 |
p. e259
|
artikel
|
| 30 |
Price cut for drug-resistant tuberculosis medicines
|
Bagcchi, Sanjeet
|
|
|
25 |
5 |
p. e264
|
artikel
|
| 31 |
Rapidly rising rates of oropharyngeal cancer and economic burden in the UK
|
Rehman, Umar
|
|
|
25 |
5 |
p. e255
|
artikel
|
| 32 |
Research in brief
|
Venkatesan, Priya
|
|
|
25 |
5 |
p. e268
|
artikel
|
| 33 |
RH5.1/Matrix-M: highlighting blood-stage malaria vaccines
|
Palacpac, Nirianne Marie Q
|
|
|
25 |
5 |
p. 472-473
|
artikel
|
| 34 |
Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled, phase 2b trial in children
|
Natama, Hamtandi M
|
|
|
25 |
5 |
p. 495-506
|
artikel
|
| 35 |
Safety, tolerability, pharmacokinetics, and antimalarial activity of MMV533: a phase 1a first-in-human, randomised, ascending dose and food effect study, and a phase 1b Plasmodium falciparum volunteer infection study
|
Bestgen, Benoit
|
|
|
25 |
5 |
p. 507-518
|
artikel
|
| 36 |
Stopping gonorrhoea's descent towards untreatability
|
The Lancet Infectious Diseases,
|
|
|
25 |
5 |
p. 471
|
artikel
|
| 37 |
Strengthening health systems
|
Sherwood-Martin, Hollie
|
|
|
25 |
5 |
p. 493
|
artikel
|
| 38 |
Targeting the SARS-CoV-2 reservoir in long COVID
|
Proal, Amy D
|
|
|
25 |
5 |
p. e294-e306
|
artikel
|
| 39 |
The effectiveness of two doses of recombinant hepatitis E vaccine in response to an outbreak in Bentiu, South Sudan: a case–control and bias indicator study
|
Nesbitt, Robin C
|
|
|
25 |
5 |
p. 537-547
|
artikel
|
| 40 |
The history of a pandemic
|
Dunsmuir, Henrietta
|
|
|
25 |
5 |
p. 492
|
artikel
|
| 41 |
Threat of HIV and tuberculosis drug resistance after US funding cuts
|
McClure, Max
|
|
|
25 |
5 |
p. e256-e257
|
artikel
|
| 42 |
Treatment of severe carbapenem-resistant Pseudomonas aeruginosa infections: still many uncertainties
|
Timsit, Jean-François
|
|
|
25 |
5 |
p. 481-483
|
artikel
|
| 43 |
Tuberculosis groups struggle with loss of US funding
|
Holt, Ed
|
|
|
25 |
5 |
p. e262
|
artikel
|
| 44 |
Will a new pentavalent meningococcal ABCWY vaccine mark a milestone in protecting all those at risk from invasive meningococcal disease?
|
Nieto-Sánchez, Claudia
|
|
|
25 |
5 |
p. 479-481
|
artikel
|
Tijdschrift beschrijving